1. Home
  2. VLO vs ARGX Comparison

VLO vs ARGX Comparison

Compare VLO & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VLO
  • ARGX
  • Stock Information
  • Founded
  • VLO 1980
  • ARGX 2008
  • Country
  • VLO United States
  • ARGX Netherlands
  • Employees
  • VLO N/A
  • ARGX N/A
  • Industry
  • VLO Integrated oil Companies
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VLO Energy
  • ARGX Health Care
  • Exchange
  • VLO Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • VLO 45.3B
  • ARGX 39.6B
  • IPO Year
  • VLO N/A
  • ARGX 2017
  • Fundamental
  • Price
  • VLO $151.99
  • ARGX $711.43
  • Analyst Decision
  • VLO Buy
  • ARGX Strong Buy
  • Analyst Count
  • VLO 15
  • ARGX 18
  • Target Price
  • VLO $154.07
  • ARGX $758.59
  • AVG Volume (30 Days)
  • VLO 2.2M
  • ARGX 379.0K
  • Earning Date
  • VLO 10-23-2025
  • ARGX 10-30-2025
  • Dividend Yield
  • VLO 2.97%
  • ARGX N/A
  • EPS Growth
  • VLO N/A
  • ARGX N/A
  • EPS
  • VLO 2.41
  • ARGX 18.75
  • Revenue
  • VLO $117,549,000,000.00
  • ARGX $3,120,821,000.00
  • Revenue This Year
  • VLO N/A
  • ARGX $77.61
  • Revenue Next Year
  • VLO N/A
  • ARGX $30.50
  • P/E Ratio
  • VLO $63.00
  • ARGX $33.77
  • Revenue Growth
  • VLO N/A
  • ARGX 88.04
  • 52 Week Low
  • VLO $99.00
  • ARGX $510.06
  • 52 Week High
  • VLO $155.12
  • ARGX $716.62
  • Technical
  • Relative Strength Index (RSI)
  • VLO 70.98
  • ARGX 73.06
  • Support Level
  • VLO $137.88
  • ARGX $697.91
  • Resistance Level
  • VLO $147.89
  • ARGX $710.00
  • Average True Range (ATR)
  • VLO 3.19
  • ARGX 11.96
  • MACD
  • VLO 1.83
  • ARGX 2.40
  • Stochastic Oscillator
  • VLO 94.27
  • ARGX 94.25

About VLO Valero Energy Corporation

Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which can produce 1.2 billion gallons per year of renewable diesel.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: